FRLN News and Press, Freeline Therapeutics Holdings plc From 08/09/22

Freeline Therapeutics press release ( NASDAQ: FRLN ): Q2 GAAP EPS of -$0.95 misses by $0.44 . Unrestricted cash and cash equivalents were $90.0 million as of June 30, 2022, as compared to $117.7 million as of year-end 2021. Freeline expects that its current level of ca...

Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued progress in FLT190 in Fabry disease and FLT201 in Gaucher disease, with new country and...

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole Jones and four other newly hired employees non-statutory options to purchase an aggregate of...

Clinical-stage biotech Freeline Therapeutics ( NASDAQ: FRLN ) traded higher in the pre-market Thursday after the company announced that the New England Journal of Medicine (NEJM) published long-term follow-up data from its Phase 1/2 B-AMAZE trial for hemophilia B therapy FLT18...

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon previously announced long-term follow-up data for up to 3.5 years from the Pha...

Gainers: Pliant Therapeutics ( PLRX ) +114% . Kaspien Holdings ( KSPN ) +99% . Iterum Therapeutics ( ITRM ) +83% . La Jolla Pharmaceutical Company ( LJPC ) +81% . Digital World Acquisition ( DWACW ) +51% . Volcon ( VLCN )...

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The t reatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announc...

LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to purchase 5,500 of the Company’s ordinary shares. The award was granted as ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congr...